Argenx price target raised to $482 from $480 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Argenx to $482 from $480 and keeps a Buy rating on the shares. The analyst now includes into the stock’s valuation some of the indications the company has most recently announced it is pursuing with efgartigimod, specifically thyroid eye disease, Sjogren’s syndrome and ANCA-associated vasculitis.